News
-
Revelation Biosciences, which announced in October 2020 that the TGA had approved plans for a Phase 1 study of its REVTx‑99 intranasal phosphorylated hexaacylated disaccharide (PHAD), said that it has now initiated the trial. According… Read more . . .
-
CDMO Kindeva Drug Delivery announced that it has broken ground on a new 137,500 sq ft headquarters building in Woodbury, MN, USA; the company anticipates that the building will be opened in the latter half… Read more . . .
-
Medigen Vaccine Biologics and BlueWillow Biologics have partnered for development of S-2P-NE-01, an intranasal vaccine against the SARS-CoV-2 virus, the companies said. According to the announcement, the vaccine will include BlueWillow’s NanoVax nasal vaccine adjuvant… Read more . . .
-
TFF Pharmaceuticals and Felix Biotechnology have signed a non-binding letter of intent for a proposed agreement regarding development of an inhaled dry powder bacteriophage for the treatment of lung infections. Felix would need to successfully… Read more . . .
-
Altimmune has signed a manufacturing agreement with Lonza for its AdCOVID intranasal vaccine candidate for the prevention of COVID-19, the companies said. In March 2020, Altimmune announced that it had partnered with the University of… Read more . . .
-
Impel NeuroPharma announced that it has submitted an NDA for its INP104 dihydroergotamine mesylate intranasal (DHE) for the treatment of migraine headaches with or without aura, which is delivered via the company’s Precision Olfactory Delivery… Read more . . .
-
Aptar has announced its acquisition of Cohero Health and all of its assets, including Cohero’s HeroTracker inhaler sensors, BreatheSmart app and platform, and mSpirometer sensors. Cohero Health CEO Joe Condurso will join Aptar Pharma. Since… Read more . . .
-
The FDA has approved Chiesi’s Bronchitol mannitol DPI for the treatment of cystic fibrosis in adult CF patients after a lengthy review process. The FDA issued a complete response letter to the original NDA in… Read more . . .
-
TFF Pharmaceuticals and Augmenta Bioworks have announced a an agreement to collaborate on development of inhaled dry powder monoclonal antibodies (mAbs) for the treatment of COVID-19 based on Augmenta’s mAbs and TFF’s thin film freezing particle… Read more . . .
-
Opiant Pharmaceuticals said that it has terminated an agreement for the use of Bespak’s Unidose Xtra device for delivery of its OPNT003 intranasal nalmefene for the treatment of opioid overdose and has entered into a… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK